you on States key Phase of program, be United today's uncontrolled Dravet to second advance approvals afternoon in good including the planned ZXXXX to who's treatment Europe. results trial in and our regulatory today from the call. to lead seeking and our seizures III catalysts late-stage submissions syndrome, for in for as pleased I'm multiple we and us joining towards speaking Brian, you, Thank everyone
in to III a the antiepileptic XXXX, enrolled trial and early designed the conducted Phase the in on a treatment XX noted, previously and final United patients trial. first double-blind two-arm we stiripentol-based regimen pivotal is are randomized per being we As planned group Study treatment patient This second quarter, our Canada enroll background in in who of States, approximately drugs. Dravet Europe patients randomized
note III patients at We we cohort in study in randomized XXXX and the pleased anticipate study scheduled are last is the total line XX June to from May. of Dravet patient that of end July. the in of syndrome early Accordingly, Phase results a efficacy announcing second Study complete the at to includes the or the top end
first FDA recall, assuming with this the positive clinical XXXX program the timeline the in trial. time type be upon. reaffirmation NDA to latest of sufficient the for for B submission. FDA you the XX-month at a to to key obtained in submission as the on Phase The FDA likely ZXXXX in result Dravet were ZXXXX the granted anticipated Study III ZXXXX was program meeting conducted in in recently rolling outcomes meeting are With the quarter. Study XXXX clinical submission for to content from the and The this a Dravet As We the support positive Dravet basis feedback filing. and agreed face-to-face the NDA for results discuss development the concurrence from a exposures Study NDA in also and syndrome NDA the FDA with that and And six-month trial, breakthrough may X, X of planned designation first therapy our based syndrome.
to path submission of in year. NDA the fourth completing be excited a to this We quarter full clear are very on the
have and to submit track by national year-end of pre-submission the authorities initiated and are addition, In EMA. with on the MAA Europe process we several meetings an in
American turn additional poster syndrome. to some regarding Now let recent held present X, At in the from Neurology, in Dravet were Angeles, updates Study highlighted additional or ZXXXX of in data presentations. AAN, two Academy pleased Los to we me Annual Meeting
stiripentol ZXXXX per X.XXX. prior tolerability. first with X, kilogram The to as had history uncontrolled prior seizures stiripentol patients In specifically convulsive XXXX highly patients in mean at was effective regimen. having to resistance failed whose p-value that Study ZXXXX, that's understanding XX for a who post-hoc milligrams total presentation treatment per on seizures ZXXXX are therapy greater patients the X.X at entry a therapy. reasons study defined whether Study in around primarily the analysis, achieved treatment XX% predicts in total day A demonstrated were reduction monthly of previously this cohort, to XX.X% that previously due and/or placebo, compared interested in seizures patients were of in convulsive controlling of failed stiripentol taking efficacy given We to of failure enrolls a stiripentol
the stiripentol XX% XX% Additionally, Study placebo XX.X% in of XX.X% X.X%, measures, respectively, statistically and from full active reduction had achieved to from who a subset with were population. patients convulsive results reduction or in and failed achieved compared baseline, the X analysis comparable group. previously the XX% groups The patients significant. efficacy seizures these placebo the an Across greater of and of and monthly or equal patients between mean group, differences were X.X in the greater than other
total full population, reduce potential ZXXXX prevalent or Dravet Study the in convulsive XX.X% types active separated Our placebo. in median XX.X% on major and second focused control presentation poster for help syndrome, X doses were significantly frequency group, group from In not just the X.X to seizure the in X.X in all the placebo the reduction seizure Both group. AAN were XX.X% in percent seizures. the
the were Year Children's Therapies poster Dr. Review: Session. from as quality-of-life The broader the new at Colorado, presentations, of a data two the to presented preliminary Emerging Knupp meeting Kelly addition presented X. Plenary of cognitive in encouraging entitled part In of function and Neurology session Study Hospital data
in function on executive of compared As significant with measures presentation, experienced those noted Knupp's Dr. select of patients life podium to on and ZXXXX treated improvement quality placebo.
our are encouraged positive of a real children significant in the such some presentation, improvements these be corporate XX-week as reach period Dravet significance until these is would of not measures Typically, these quality study, of time. gains physicality, longer note, our posted short-term to included by expected a syndrome. life initial within are after reflecting Please with now to We signals cognition current of on treatment website. which see and on data
may treatment enrolled XXXX. syndrome extension patients Dravet over our As studies eligible with who our open-label Study roll into core ZXXXX a clinical are trial, reminder, to in continue
We see in the robust continue very to participation trial. open-label extension
approximately end XX% open-label these of patients for study XXX the at April, patients trial, been Of and one extension have patients treatment least As have of today. open-label over now in note, the the patients than six XX in entered of months over more XX% these have remaining year. of with exceeded
now X continues study to population target of to for open-label the monitoring for periodic valvulopathy the a safety syndrome. like via date review in of there or has pulmonary patients second study echocardiography provide have Lennox-Gastaut by larger with safety committee, no current indication formal cardiac clinical cases to ZXXXX, extension or update in on the have population Xx program been data concerns than and any arisen Syndrome I'd which patients and all no monitoring While cardiac a our in patient. approximately you Dravet an LGS, hypertension patient safety
efficacy with tolerability randomized study age ongoing and patients added is placebo-controlled assess XX to double-blind Phase antiepileptic III multicenter three-arm The XXXX, when trial, to XXX the patients. LGS targeting Study Our pediatric in a global of to current safety, of therapy. total and patient's adult is a ZXXXX study a up
April, Canada the the open sites XX United recruit had we end to into and of Study in XXXX. of As patients States
submissions America We are other countries. in for North sites submit continuing to approvals several open and European Committee in to Ethics
pleased initial year XXXX. We study enrollment our I on will of to for the a reiterate patients last Phase this call, in what indication. be that said of global III with Study enrollment for second have said, XXXX With our been
granted line over not the XXXX. quarter summary, our of this anticipate carried we study from this As such, breakthrough are we data Dravet rotary to into subsequent to us strong ZXXXX do a remaining interaction in position The designation milestones have first in in strong XXXX XXXX. top successful syndrome from has to therapy very key pleased our In and our placed year. before FDA's momentum on execute
forward outcome in in of for call Dravet Europe syndrome U.S. of I the over will looking to Pending the quarter year. III we top that, first, Mike intend XXXX, ZXXXX are, fourth this approvals for second to in Study review the his We and regulatory Mike? study, now financials. successful our file turn the With to data XXXX, from Study Phase for a reporting shortly. line in
